UGA Biopharma Featured in Waters Case Study on Automated Glycan Analysis

Published on February 25, 2026

Due to its strong commitment and scientific responsibility toward clients and their patients, UGA Biopharma considers state-of-the-art technological laboratories a fundamental requirement. The development of robust analytical methods for biologics and biosimilars are essential standards that we consistently adhere to. Accordingly, UGA actively engages in testing and validating various technologies across multiple levels of development.

Recently, Mr. Sazzad Ul Karim from the Analysis & DSP Department, evaluated the application of the Andrew+™ pipetting robot from Waters Corporation for automated glycan analysis in biosimilar development.